Published in J Neurosci on February 03, 2010
Genetic animal models of Parkinson's disease. Neuron (2010) 3.86
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci (2010) 3.14
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A (2010) 2.34
Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain. J Neurosci (2012) 2.06
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Dopamine release in the basal ganglia. Neuroscience (2011) 1.67
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis (2010) 1.60
Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One (2011) 1.38
Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener (2012) 1.34
Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One (2012) 1.21
Parkinson's disease: animal models and dopaminergic cell vulnerability. Front Neuroanat (2014) 1.18
Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord (2012) 1.17
Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am J Pathol (2012) 1.16
Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15
Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One (2011) 1.15
Cntnap4 differentially contributes to GABAergic and dopaminergic synaptic transmission. Nature (2014) 1.14
Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog Neurobiol (2011) 1.14
Parkinson's disease: a model dilemma. Nature (2010) 1.11
Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet (2012) 1.10
Modeling neurodegeneration in zebrafish. Curr Neurol Neurosci Rep (2011) 1.09
Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends Pharmacol Sci (2012) 1.04
Toxin-induced and genetic animal models of Parkinson's disease. Parkinsons Dis (2010) 1.04
Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. ACS Chem Neurosci (2012) 1.04
High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One (2012) 1.03
The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis (2013) 1.03
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Front Mol Neurosci (2014) 1.01
The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis (2011) 0.99
Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int J Biol Sci (2011) 0.98
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis (2015) 0.97
α-synuclein, LRRK2 and their interplay in Parkinson's disease. Future Neurol (2012) 0.97
LRRK2 pathobiology in Parkinson's disease. J Neurochem (2014) 0.97
Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain. Mol Cell Biol (2014) 0.96
Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. J Comp Neurol (2014) 0.96
Limitations of animal models of Parkinson's disease. Parkinsons Dis (2010) 0.96
Dopaminergic expression of the Parkinsonian gene LRRK2-G2019S leads to non-autonomous visual neurodegeneration, accelerated by increased neural demands for energy. Hum Mol Genet (2013) 0.95
Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications. Mov Disord (2011) 0.95
Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics (2014) 0.94
LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol (2013) 0.94
Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. Nat Commun (2015) 0.94
Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice. PLoS One (2013) 0.93
Dysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegans. PLoS One (2011) 0.91
Dysregulation of striatal dopamine release in a mouse model of dystonia. J Neurochem (2010) 0.91
Models for LRRK2-Linked Parkinsonism. Parkinsons Dis (2011) 0.91
Mitochondrial dysfunction in genetic animal models of Parkinson's disease. Antioxid Redox Signal (2011) 0.90
Short- and long-term effects of LRRK2 on axon and dendrite growth. PLoS One (2013) 0.90
Parkinson's disease and immune system: is the culprit LRRKing in the periphery? J Neuroinflammation (2012) 0.88
LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis. Exp Neurol (2014) 0.88
Synaptic dysfunction in genetic models of Parkinson's disease: a role for autophagy? Neurobiol Dis (2010) 0.88
Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats. Neurobiol Aging (2014) 0.87
Genetically engineered mouse models of Parkinson's disease. Brain Res Bull (2011) 0.86
Cellular processes associated with LRRK2 function and dysfunction. FEBS J (2015) 0.86
Premotor biomarkers for Parkinson's disease - a promising direction of research. Transl Neurodegener (2012) 0.86
Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors. Anal Biochem (2010) 0.86
Parkinson's disease mouse models in translational research. Mamm Genome (2011) 0.85
Transgenic animal models of neurodegeneration based on human genetic studies. J Neural Transm (Vienna) (2010) 0.85
LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization. PLoS One (2013) 0.84
Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application. Parkinsonism Relat Disord (2012) 0.84
Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity. Hum Mol Genet (2011) 0.84
Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiol Dis (2014) 0.84
Disruption of LRRK2 does not cause specific loss of dopaminergic neurons in zebrafish. PLoS One (2011) 0.83
Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers. Neurology (2014) 0.83
Orchestrated increase of dopamine and PARK mRNAs but not miR-133b in dopamine neurons in Parkinson's disease. Neurobiol Aging (2014) 0.83
LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate. Mol Neurodegener (2016) 0.83
The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. Hum Mol Genet (2015) 0.83
A novel GTP-binding inhibitor, FX2149, attenuates LRRK2 toxicity in Parkinson's disease models. PLoS One (2015) 0.82
The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities. Mol Neurodegener (2012) 0.82
Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression. Hum Mol Genet (2015) 0.82
Non-motor and motor features in LRRK2 transgenic mice. PLoS One (2013) 0.81
Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts. Proc Natl Acad Sci U S A (2016) 0.81
Mouse models of Parkinson's disease associated with mitochondrial dysfunction. Mol Cell Neurosci (2012) 0.81
Functional Impairment in Miro Degradation and Mitophagy Is a Shared Feature in Familial and Sporadic Parkinson's Disease. Cell Stem Cell (2016) 0.81
Genetic ablation of PLA2G6 in mice leads to cerebellar atrophy characterized by Purkinje cell loss and glial cell activation. PLoS One (2011) 0.81
G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons. J Neurosci (2016) 0.80
LRRK2 mutations and neurotoxicant susceptibility. Exp Biol Med (Maywood) (2015) 0.79
The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research. Biochem J (2016) 0.79
Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation. J Neurosci (2016) 0.79
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. Neurobiol Dis (2014) 0.78
SKF-83566, a D1-dopamine receptor antagonist, inhibits the dopamine transporter. J Neurochem (2011) 0.78
The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus. J Neurosci (2015) 0.78
Interactive effects of age and multi-gene profile on motor learning and sensorimotor adaptation. Neuropsychologia (2016) 0.77
Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo. Neurobiol Aging (2015) 0.77
ULK1 and JNK are involved in mitophagy incurred by LRRK2 G2019S expression. Protein Cell (2013) 0.77
LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function. Hum Mol Genet (2016) 0.77
Unaltered striatal dopamine release levels in young Parkin knockout, Pink1 knockout, DJ-1 knockout and LRRK2 R1441G transgenic mice. PLoS One (2014) 0.76
Mouse Genetic Models of Human Brain Disorders. Front Genet (2016) 0.76
LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives. Clin Pharmacol (2016) 0.76
Transgenic LRRK2 (R1441G) rats-a model for Parkinson disease? PeerJ (2015) 0.75
G2019S LRRK2 and aging confer susceptibility to proteasome inhibitor-induced neurotoxicity in nigrostriatal dopaminergic system. J Neural Transm (Vienna) (2015) 0.75
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice. Acta Neuropathol Commun (2017) 0.75
Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology. eNeuro (2017) 0.75
Characterization of Optically and Electrically Evoked Dopamine Release in Striatal Slices from Digenic Knock-in Mice with DAT-Driven Expression of Channelrhodopsin. ACS Chem Neurosci (2017) 0.75
Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor. ACS Med Chem Lett (2012) 0.75
Endogenous Leucine-Rich Repeat Kinase 2 Slows Synaptic Vesicle Recycling in Striatal Neurons. Front Synaptic Neurosci (2017) 0.75
Biopterin levels in the cerebrospinal fluid of patients with PARK8 (I2020T). J Neural Transm (Vienna) (2011) 0.75
LRRKing up the right trees? On figuring out the effects of mutant LRRK2 and other Parkinson's disease-related genes. Basal Ganglia (2013) 0.75
Unraveling protein misfolding diseases using model systems. Future Sci OA (2015) 0.75
Low-variance RNAs identify Parkinson's disease molecular signature in blood. Mov Disord (2015) 0.75
Proposed Motor Scoring System in a Porcine Model of Parkinson's Disease induced by Chronic Subcutaneous Injection of MPTP. Exp Neurobiol (2014) 0.75
The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions. Sci Rep (2017) 0.75
Models of LRRK2-Associated Parkinson's Disease. Adv Neurobiol (2017) 0.75
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron (2000) 6.92
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis (2006) 5.96
Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci (2006) 5.32
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron (2006) 4.51
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem (2003) 4.36
LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med (2006) 3.90
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J (2007) 3.89
Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J (2008) 3.51
Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci U S A (2007) 3.50
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet (2005) 3.49
BAC to the future: the use of bac transgenic mice for neuroscience research. Nat Rev Neurosci (2001) 3.32
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci U S A (1998) 3.12
Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A (2005) 3.00
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro (2009) 2.85
GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry (2007) 2.71
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci (2004) 2.64
Roc, a Ras/GTPase domain in complex proteins. Biochim Biophys Acta (2003) 2.62
Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci (1990) 2.60
Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci (2009) 2.47
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem (2007) 2.40
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A (2009) 2.28
The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res (2007) 2.27
A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A (2008) 2.12
Determination of release and uptake parameters from electrically evoked dopamine dynamics measured by real-time voltammetry. J Neurosci Methods (2001) 2.03
Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem Biophys Res Commun (2007) 1.78
LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr Biol (2007) 1.76
Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem (2005) 1.75
Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices. Neuropharmacology (2007) 1.68
Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and synaptic vesicle stores. J Neurosci (2001) 1.68
Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet (2007) 1.65
Dynamic observation of dopamine autoreceptor effects in rat striatal slices. J Neurochem (1992) 1.48
Time window of autoreceptor-mediated inhibition of limbic and striatal dopamine release. Synapse (2002) 1.46
Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol Neurodegener (2008) 1.37
Glutamate-dependent inhibition of dopamine release in striatum is mediated by a new diffusible messenger, H2O2. J Neurosci (2003) 1.33
Mobilization of calcium from intracellular stores facilitates somatodendritic dopamine release. J Neurosci (2009) 1.19
Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. Neurology (2008) 1.18
Interaction between diffusion and Michaelis-Menten uptake of dopamine after iontophoresis in striatum. Biophys J (1995) 1.17
"Real time" measurement of endogenous dopamine release during short trains of pulses in slices of rat neostriatum and nucleus accumbens: role of autoinhibition. Naunyn Schmiedebergs Arch Pharmacol (1991) 1.04
Regional differences in evoked dopamine efflux in brain slices of rat anterior and posterior caudate putamen. Naunyn Schmiedebergs Arch Pharmacol (1992) 1.01
Limited regulation of somatodendritic dopamine release by voltage-sensitive Ca channels contrasted with strong regulation of axonal dopamine release. J Neurochem (2006) 1.00
AMPA receptor-dependent H2O2 generation in striatal medium spiny neurons but not dopamine axons: one source of a retrograde signal that can inhibit dopamine release. J Neurophysiol (2008) 0.99
Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease. J Biol Chem (2008) 0.93
Investigating convergent actions of genes linked to familial Parkinson's disease. Neurodegener Dis (2008) 0.91
Modelling constant potential amperometry for investigations of dopaminergic neurotransmission kinetics in vivo. J Neurosci Methods (2001) 0.85
Analytical characterization of a sensitive radioassay for tyrosine hydroxylase activity in rodent striatum. Neurochem Res (2004) 0.80
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Functional impact of global rare copy number variation in autism spectrum disorders. Nature (2010) 14.66
Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell (2007) 14.63
Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05
Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature (2012) 13.71
WEGO: a web tool for plotting GO annotations. Nucleic Acids Res (2006) 13.06
Using FlyAtlas to identify better Drosophila melanogaster models of human disease. Nat Genet (2007) 12.62
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol (2008) 10.42
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Sleep drives metabolite clearance from the adult brain. Science (2013) 9.65
Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature (2009) 9.47
MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell (2007) 9.33
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17
Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol (2010) 9.01
Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med (2014) 8.73
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature (2009) 7.39
Distinct regulation of autophagic activity by Atg14L and Rubicon associated with Beclin 1-phosphatidylinositol-3-kinase complex. Nat Cell Biol (2009) 6.69
A draft sequence for the genome of the domesticated silkworm (Bombyx mori). Science (2004) 6.62
Diffusion in brain extracellular space. Physiol Rev (2008) 5.34
Synaptic, transcriptional and chromatin genes disrupted in autism. Nature (2014) 5.30
A genetic variation map for chicken with 2.8 million single-nucleotide polymorphisms. Nature (2004) 5.24
Self-monitoring in weight loss: a systematic review of the literature. J Am Diet Assoc (2011) 5.12
AlleleSeq: analysis of allele-specific expression and binding in a network framework. Mol Syst Biol (2011) 4.71
The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science (2009) 4.63
The Beclin 1-VPS34 complex--at the crossroads of autophagy and beyond. Trends Cell Biol (2010) 4.15
Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol (2004) 3.95
Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration. Proc Natl Acad Sci U S A (2007) 3.92
Glycolytic enzymes can modulate cellular life span. Cancer Res (2005) 3.78
Phosphatidylinositol 4 phosphate regulates targeting of clathrin adaptor AP-1 complexes to the Golgi. Cell (2003) 3.75
Large-gap quantum spin Hall insulators in tin films. Phys Rev Lett (2013) 3.60
Regulation of OsSPL14 by OsmiR156 defines ideal plant architecture in rice. Nat Genet (2010) 3.56
Genome dynamics and diversity of Shigella species, the etiologic agents of bacillary dysentery. Nucleic Acids Res (2005) 3.56
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet (2010) 3.42
Genome-wide analyses of exonic copy number variants in a family-based study point to novel autism susceptibility genes. PLoS Genet (2009) 3.42
In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc Natl Acad Sci U S A (2006) 3.37
Induction of autophagy in axonal dystrophy and degeneration. J Neurosci (2006) 3.28
A new testing strategy to identify rare variants with either risk or protective effect on disease. PLoS Genet (2011) 3.13
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature (2010) 3.09
HIV/STD risk behaviors and perceptions among rural-to-urban migrants in China. AIDS Educ Prev (2004) 3.04
Evolution of the immunoglobulin heavy chain class switch recombination mechanism. Adv Immunol (2007) 2.94
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1. Cell Metab (2008) 2.84
Variants in the fat mass- and obesity-associated (FTO) gene are not associated with obesity in a Chinese Han population. Diabetes (2007) 2.83
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Altered ultrasonic vocalization in mice with a disruption in the Foxp2 gene. Proc Natl Acad Sci U S A (2005) 2.76
Sequencing of the sea lamprey (Petromyzon marinus) genome provides insights into vertebrate evolution. Nat Genet (2013) 2.76
Rapid cardiotonic effects of lipid emulsion infusion*. Crit Care Med (2013) 2.76
BGI-RIS: an integrated information resource and comparative analysis workbench for rice genomics. Nucleic Acids Res (2004) 2.69
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Trends in physical activity, sedentary behavior, diet, and BMI among US adolescents, 2001-2009. Pediatrics (2013) 2.66
Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science (2006) 2.62
A developmental approach to complex PTSD: childhood and adult cumulative trauma as predictors of symptom complexity. J Trauma Stress (2009) 2.59
Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA (2013) 2.58
Glutamatergic signaling by mesolimbic dopamine neurons in the nucleus accumbens. J Neurosci (2010) 2.53
PDGF signalling controls age-dependent proliferation in pancreatic β-cells. Nature (2011) 2.53
The effect of passengers and risk-taking friends on risky driving and crashes/near crashes among novice teenagers. J Adolesc Health (2011) 2.53
Involvement of the ubiquitin-proteasome system in the early stages of wallerian degeneration. Neuron (2003) 2.51
Physics. Learning and scientific reasoning. Science (2009) 2.49
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
PILRalpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B. Cell (2008) 2.49
A glimpse of streptococcal toxic shock syndrome from comparative genomics of S. suis 2 Chinese isolates. PLoS One (2007) 2.47
Individual common variants exert weak effects on the risk for autism spectrum disorderspi. Hum Mol Genet (2012) 2.46
Rare complete knockouts in humans: population distribution and significant role in autism spectrum disorders. Neuron (2013) 2.45
Sequence kernel association tests for the combined effect of rare and common variants. Am J Hum Genet (2013) 2.41
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem (2007) 2.40
Microarrays: retracing steps. Nat Med (2007) 2.39
The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain (2007) 2.30
Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci (2004) 2.28
Crystal structure of the clathrin adaptor protein 1 core. Proc Natl Acad Sci U S A (2004) 2.28
BMP4 supports self-renewal of embryonic stem cells by inhibiting mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A (2004) 2.25
Crash and risky driving involvement among novice adolescent drivers and their parents. Am J Public Health (2011) 2.25
Historical variations in mutation rate in an epidemic pathogen, Yersinia pestis. Proc Natl Acad Sci U S A (2012) 2.22
The completion of the Mammalian Gene Collection (MGC). Genome Res (2009) 2.21
Influenza Virus Database (IVDB): an integrated information resource and analysis platform for influenza virus research. Nucleic Acids Res (2006) 2.14
Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology (2012) 2.11
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res (2013) 2.09
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Increased expression of CYP17 and CYP11B1 in subclinical Cushing's syndrome due to adrenal adenomas. Int J Urol (2011) 2.07
Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of α-synuclein and LRRK2 in the brain. J Neurosci (2012) 2.06
Applications of beta-mixture models in bioinformatics. Bioinformatics (2005) 2.04
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology (2014) 2.04
A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron (2005) 2.03
Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr (2010) 2.01
A comprehensive approach to the analysis of matrix-assisted laser desorption/ionization-time of flight proteomics spectra from serum samples. Proteomics (2003) 2.01
DAncing past the DAT at a DA synapse. Trends Neurosci (2004) 2.00
Wld S requires Nmnat1 enzymatic activity and N16-VCP interactions to suppress Wallerian degeneration. J Cell Biol (2009) 1.98
A novel CCCH-zinc finger protein family regulates proinflammatory activation of macrophages. J Biol Chem (2008) 1.98
How many human genes can be defined as housekeeping with current expression data? BMC Genomics (2008) 1.97
The class IA phosphatidylinositol 3-kinase p110-beta subunit is a positive regulator of autophagy. J Cell Biol (2010) 1.91